Comparative Pharmacology
Head-to-head clinical analysis: BUPRENEX versus PIVYA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUPRENEX versus PIVYA.
BUPRENEX vs PIVYA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial agonist at mu-opioid receptors; weak antagonist at kappa-opioid receptors.
Pivya (pivmecillinam) is a prodrug of mecillinam, a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding protein 2 (PBP2), leading to defective cell wall formation and cell death.
0.3 mg intramuscularly or intravenously every 6 hours as needed for pain; may repeat once after 30-60 minutes if needed.
1200 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 37 hours (range 20-70 hours) due to slow dissociation from mu-opioid receptors, contributing to prolonged clinical effects.
Terminal elimination half-life of 3-4 hours in patients with normal renal function; may be prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
Buprenorphine is primarily eliminated via fecal excretion (70%) as unchanged drug and metabolites, with renal excretion accounting for approximately 10-30% of the dose.
Primarily renal excretion as unchanged drug (approximately 70-80%); biliary/fecal excretion accounts for 10-15%.
Category C
Category C
Opioid Partial Agonist
Opioid Partial Agonist